Intraductal papillary mucinous neoplasm (IPMN)

An IPMN (Intraductal Papillary Mucinous Neoplasm) is a type of fluid-filled sac, or cyst, that grows inside the drainage tubes of your pancreas. Unlike harmless cysts, IPMNs produce a thick slime (mucus) and have small, finger-like growths inside them. While many IPMNs are low-risk, they exist on a spectrum from low-grade dysplasia to high-grade dysplasia and invasive cancer. The key clinical challenge is identifying which lesions require surveillance and which should be treated. They are classified by their anatomical relationship to the pancreatic duct system:

• Main duct IPMN grows in the pancreas's central fluid tube. This type has the highest risk of turning into cancer and is often considered for surgical removal.

• Branch duct IPMN grows in the smaller side tubes, looking like a tiny cluster of grapes. These are much lower risk and are usually just watched closely unless they grow large.

• Mixed-type IPMN involves both the main tube and the side branches, carrying the same higher risks as a main duct type.

IPMNs are graded histologically by the degree of cellular abnormality from low-grade dysplasia through high-grade dysplasia to invasive carcinoma. The goal of surveillance and treatment is to identify and resect lesions before high-grade dysplasia or invasion develops.

Symptoms of IPMN

The majority of IPMNs, particularly small branch duct lesions, cause no symptoms and are discovered entirely incidentally on abdominal imaging. When symptoms occur they reflect ductal obstruction, pancreatitis, or malignant transformation:

• Vague upper abdominal discomfort or pain, particularly after eating

• Nausea and changes in digestion from pancreatic exocrine dysfunction

• New-onset diabetes or worsening of existing diabetes from pancreatic endocrine involvement

• Unexplained weight loss, a concerning symptom suggesting significant pancreatic dysfunction or malignant change

• Acute or recurrent pancreatitis from ductal obstruction by mucin

• Jaundice from bile duct obstruction in pancreatic head lesions

• Steatorrhoea, pale, fatty, foul-smelling stools from pancreatic exocrine insufficiency

The presence of symptoms significantly increases the probability of high-grade dysplasia or malignancy and is a strong indicator for surgical evaluation.

What causes IPMNs?

The exact cause of IPMN development is not fully understood. Contributing factors include:

• Somatic mutations in KRAS, GNAS, and RNF43 genes are the most commonly identified molecular alterations in IPMNs, driving abnormal epithelial proliferation within the pancreatic duct.

• Age IPMNs are predominantly a disease of older adults, with peak incidence in the sixth and seventh decades. Their prevalence on cross-sectional imaging increases significantly with age.

• Genetic predisposition familial pancreatic cancer syndromes including BRCA2, PALB2, ATM, and Lynch syndrome mutations are associated with higher IPMN prevalence and increased malignant transformation risk.

• Chronic pancreatitis inflammation is associated with IPMN development through shared mechanisms of ductal epithelial injury.

• Smoking is associated with increased IPMN prevalence and may accelerate malignant transformation.

• Diabetes mellitus is associated with both IPMN development and as a consequence of progressive pancreatic dysfunction from the lesion itself.

How is an IPMN detected?

IPMNs are detected through abdominal imaging, with blood tests providing metabolic context and identifying signs of pancreatic dysfunction.

Abdominal MRI and MRCP Elfcare’s full-body MRI includes advanced pancreas imaging (MRCP) to spot fluid-filled cysts like IPMNs, making it one of our most vital life-saving checks. The scan measures the size of your pancreas tubes and checks for high-risk warning signs, such as cysts larger than 3 cm, thickened walls, or severely widened ducts, that could signal a hidden cancer risk. Catching an IPMN early on your scan allows doctors to step in and monitor or treat it long before it can turn into a serious illness.

Blood tests cannot detect IPMNs directly but assess pancreatic function, metabolic health, and systemic markers relevant to the clinical context. Relevant markers in Elfcare's panel include:

• HbA1c and glucose new-onset or worsening diabetes can occur with pancreatic dysfunction and may provide additional clinical context when an IPMN is present

• ALT, AST, GGT, ALP, and bilirubin liver and biliary markers assess for bile duct obstruction from pancreatic head IPMNs, with elevated ALP and bilirubin indicating obstructive jaundice requiring urgent assessment

• Albumin low albumin from malnutrition or pancreatic exocrine insufficiency reflects the systemic impact of significant pancreatic disease

• CRP systemic inflammation relevant to pancreatitis as a complication of ductal obstruction by mucin

• Lipid profile pancreatic exocrine dysfunction affects fat digestion and absorption, with consequences for lipid metabolism

• Haemoglobin and full blood count anaemia can accompany malignant IPMN from chronic disease or blood loss

Why early detection matters

Pancreatic cancer is one of the most lethal cancers, with a five-year survival below 12% for all-comers largely because it is almost always diagnosed at an advanced, unresectable stage. IPMN represents one of the few opportunities to identify pancreatic malignancy at a pre-invasive or early invasive stage, when surgical resection is curative. Main duct IPMN with high-grade dysplasia resected before invasion carries an excellent long-term prognosis. The same lesion identified after invasion has occurred carries a prognosis comparable to de novo pancreatic cancer. Branch duct IPMNs identified early allow for risk-stratified surveillance, with lesions developing worrisome features identified and resected before malignant transformation. An IPMN found incidentally on Elfcare's abdominal MRI in an asymptomatic person is the ideal scenario for pancreatic cancer prevention.

How Elfcare can help

Elfcare's full body MRI images the pancreas as part of its abdominal imaging and can identify cystic pancreatic lesions, including IPMNs. MRI can also provide information about pancreatic duct anatomy and features that may help determine whether specialist assessment is needed.

Our blood panel covers HbA1c, liver and biliary markers, albumin, CRP, and metabolic markers, providing the functional pancreatic and systemic context alongside the structural MRI findings.

If our MRI or blood tests identify an IPMN or findings consistent with a cystic pancreatic lesion, we take care of further diagnostics or refer you to the appropriate specialist.